25O - International comparison of treatment and survival for pleural mesothelioma, combined analysis of 9.014 patients from Belgium, the Netherlands and E...

Date 28 March 2014
Event ELCC 2014
Session Proffered papers 3 - Screening, staging and epidemiology
Topics Cancer Aetiology, Epidemiology, Prevention
Presenter Jan van Meerbeeck
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors J.P. van Meerbeeck1, R.A. Damhuis2, A. Khakwani3, H. De Schutter4, A. Rich3, S.A. Burgers5
  • 1Thoracic Oncology, U.Z.A. University Hospital Antwerp, 2650 - Edegem/BE
  • 2None, Comprehensive Cancer Centre, Utrecht/NL
  • 3Division Of Epidemiology & Public Health, University of Nottingham, Nottingham/UK
  • 4None, Belgian Cancer Registry, Brussels/BE
  • 5Thoracic Oncology, Netherlands Cancer Institute, Amsterdam/NL



Pleural mesothelioma is refractory to treatment and has a poor prognosis. Only chemotherapy was proven effective in randomized trials. Novel chemotherapy may increase median survival by several months and was gradually introduced in the period 2003–2006. Little is known about contemporary treatment practice in Europe. To determine patterns of care and current survival rates, three large population-based registries were queried in a uniform manner.